Screener
Opus Genetics IRD Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 10,577 | 7,953 |
| General and administrative | 5,944 | 6,346 |
| Total operating expenses | 16,521 | 14,299 |
| Loss from operations | (14,364) | (9,929) |
| Fair value change in warrant liabilities | (51,364) | 2,805 |
| Financing costs | (582) | (1,372) |
| Interest expense | (69) | — |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's total operating expenses?
- Opus Genetics (IRD) reported total operating expenses of $16.52M in Q1 2026.
- How has Opus Genetics's total operating expenses changed year-over-year?
- Opus Genetics's total operating expenses increased by 15.5% year-over-year, from $14.3M to $16.52M.
- What is the long-term trend for Opus Genetics's total operating expenses?
- Over 4 years (2021 to 2025), Opus Genetics's total operating expenses has grown at a 22.7% compound annual growth rate (CAGR), from $23.29M to $52.8M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Opus Genetics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude